DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

PHASE4CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

May 1, 2020

Study Completion Date

April 30, 2021

Conditions
Ventricular TachycardiaPremature Ventricular ContractionStroke
Interventions
DRUG

DOAC

DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.

DRUG

Aspirin

Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.

Trial Locations (5)

10467

Montefiore Medical Center, The Bronx

66160

University of Kansas Medical Center, Kansas City

66221

KCHRF, Overland Park

78701

TCAI, Austin

Unknown

Jayadeva Institute of Medical Sciences, Bengaluru

All Listed Sponsors
collaborator

Kansas City Heart Rhythm Research Foundation

OTHER

lead

Kansas City Heart Rhythm Institute

OTHER

NCT02666742 - DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation | Biotech Hunter | Biotech Hunter